• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300636.SZ
Share

Jiangxi Synergy Pharmaceutical Co., Ltd. Stocks

CN¥ 6.95Last Updated 15.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 413.38M

CN¥ 6.95
Key Takeaways

Risk factor

Vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Somewhat favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Yichun, People's Republic of China, Jiangxi Synergy Pharmaceutical Co., Ltd. was established in 2004. The company specializes in the global production and sale of active pharmaceutical ingredients (APIs), as well as liquid crystal compounds and various chemical intermediates.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 300636.SZ is 8.50 and suggests 25.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.07.2026 03:25

Apple Is on the Hunt for AI Chip Makers — The Information

16.07.2026 02:05

JPMorgan, BlackRock, and Goldman plan to tokenize stocks and government bonds

16.07.2026 01:11

OpenAI has unveiled its first gadget—a keyboard for controlling AI agents

16.07.2026 00:42

"The rumors are completely false": Lucid denies risk of bankruptcy, shares soar 30%

16.07.2026 00:02

Wall Street's leading tech optimist has launched his own investment bank

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026